Beverly Jarema, DO
Family Medicine · Saginaw, MINPI 1104834563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 370 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 370 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$551
- Bayer$477
- Lilly USA, LLC$477
- GSK$427
- Pfizer$406
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,871100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,146 |
| AstraZeneca | 31 | $551 |
| Bayer | 26 | $477 |
| Lilly USA, LLC | 31 | $477 |
| GSK | 27 | $427 |
| Pfizer | 42 | $406 |
| Merck | 17 | $287 |
| Astellas Pharma US Inc | 14 | $261 |
| Amgen | 13 | $220 |
| Sanofi-aventis U.S. LLC | 13 | $217 |
| AbbVie(2 entities) | 9 | $194 |
| Boehringer Ingelheim | 12 | $194 |
| Nestle Healthcare Nutrition Inc. | 9 | $173 |
| Exact Sciences | 7 | $153 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Organon | 4 | $74 |
| Abbott | 4 | $69 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Amarin Pharma, Inc. | 3 | $49 |
| Aimmune Therapeutics, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Novartis | 1 | $31 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Recor Medical Inc | 1 | $14 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
How this compares
$5,871 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 29 | $52,600 |
| EliquisApixaban | 40 | $31,069 |
| MounjaroTirzepatide | 19 | $28,274 |
| OzempicSemaglutide | 22 | $27,973 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $27,377 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $23,673 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $17,070 |
| Bydureon BciseExenatide Microspheres | 12 | $15,876 |
| FarxigaDapagliflozin Propanediol | 17 | $12,893 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,408 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $4,005 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $3,725 |
| Metoprolol Succinate | 167 | $3,467 |
| Levothyroxine Sodium | 238 | $2,901 |
| Rosuvastatin Calcium | 123 | $2,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $194 | $58,00840 claims |
| PfizerEliquis | $406 | $31,06940 claims |
| Lilly USA, LLCMounjaro | $477 | $28,27419 claims |
| Novo NordiskOzempic | $1,146 | $27,97322 claims |
| GSKTrelegy Ellipta | $427 | $23,67324 claims |
| AstraZenecaFarxiga | $551 | $12,89317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Saginaw
- Joseph NatoleSaginaw$16K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.